Figure 2
Figure 2. dnPPARγ overexpression causes expansion and abnormality of myeloid cells. (A) Flow cytometry analysis of the BM, blood, spleens, and lungs from 3-month doxycycline-treated (+DOX) or untreated (−DOX) c-fms-rtTA/(tetO)7-CMV-dnPPARγ–bitransgenic mice. A representative analysis of the percentage of CD11b+GR-1+ cells is presented. (B) Percentage of CD11b+GR-1+ cells in 3-month doxycycline-treated or untreated bitransgenic mice. (C) Total numbers of CD11b+GR-1+ cells in 3-month doxycycline-treated or untreated bitransgenic mice. (D) Representative flow cytometry analysis of pStat3 in CD11b+GR-1+ cells from BM, blood, spleens, and lungs of 3-month doxycycline-treated or untreated bitransgenic mice. (E) Percentages of pStat3, pErk, pNFκB, and pP38 in 3-month doxycycline-treated or untreated bitransgenic mice were statistically analyzed. Values are means ± SD (n > 5). * P < .05; ** P < .01.

dnPPARγ overexpression causes expansion and abnormality of myeloid cells. (A) Flow cytometry analysis of the BM, blood, spleens, and lungs from 3-month doxycycline-treated (+DOX) or untreated (−DOX) c-fms-rtTA/(tetO)7-CMV-dnPPARγ–bitransgenic mice. A representative analysis of the percentage of CD11b+GR-1+ cells is presented. (B) Percentage of CD11b+GR-1+ cells in 3-month doxycycline-treated or untreated bitransgenic mice. (C) Total numbers of CD11b+GR-1+ cells in 3-month doxycycline-treated or untreated bitransgenic mice. (D) Representative flow cytometry analysis of pStat3 in CD11b+GR-1+ cells from BM, blood, spleens, and lungs of 3-month doxycycline-treated or untreated bitransgenic mice. (E) Percentages of pStat3, pErk, pNFκB, and pP38 in 3-month doxycycline-treated or untreated bitransgenic mice were statistically analyzed. Values are means ± SD (n > 5). * P < .05; ** P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal